Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Beam Therapeutics

bluebird bio

Cellectis SA

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.

7 Gene Editing Stocks Promising to Change our DNA

The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Read Next:   FDA Expands EUA for Lower Dose Subcutaneous Version of Regeneron's COVID-19 Antibody Cocktail.

U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy

Shares of Regeneron Pharmaceuticals Inc. REGN, +0.88% gained 2.1% in premarket trading on Wednesday, the day after the company said the U.S. government had purchased an additional 1.4 million doses of its monoclonal antibody treatment for COVID-19 for $2.9 billion. The treatment, which costs $2,100 per dose, is free to Americans at high risk of hospitalization and death who have tested positive or have been exposed to the virus.

U.S. to pay $2.9 billion for an additional 1.4 million doses of Regeneron's COVID-19 therapy

TARRYTOWN, N.Y., Sept. 14, 2021 /PRNewswire/ -- New agreement for 1.4 million doses of REGEN-COV, brings total purchased by the U.S. government to nearly 3 million doses REGEN-COV currently authorized to treat certain infected patients to reduce risk of hospitalization or death from COVID-19, and for post-exposure prophylaxis for close contacts of infected individuals Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Department of Health and Human Services (HHS) and the Department of Defense (DOD) will purchase 1.4 million additional doses of REGEN-COV (casirivimab and imdevimab).

Regeneron Announces New U.S. Government Agreement to Purchase Additional Doses of REGEN-COV™ (casirivimab and imdevimab) Antibody Cocktail

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

CBRE Group

KLA-Tencor

T. Rowe Price Group

Whirlpool

T. Rowe Price Group (TROW), KLA Corporation (KLAC), Whirlpool Corporation (WHR), CBRE Group (CBRE) and Regeneron Pharmaceuticals (REGN) are some stocks with high ROE to buy as markets slip on weak jobs report.

5 Stocks With High ROE as Markets Stumble on Tepid Jobs Report

Canon

Cabot Oil & Gas

Exelon

Walmart

It is imperative to build a portfolio of low-beta stocks to sail through a choppy market. REGN, CAJ, COG, EXC & WMT are well poised to gain.

Bet on These 5 Low-Beta Stocks to Combat Market Volatility

Regeneron's (REGN) performance in the year has gained from higher demand for its antibody cocktail - REGEN-COV.

Will Regeneron's (REGN) Antibody Cocktail Fuel Further Growth?

DocuSign

MongoDB

In the stock market, what goes up doesn't have to come down.

3 Hot Stocks to Buy in September

Moderna

Vertex Pharmaceuticals

REGN, MRNA & VRTX are the three biotech companies that are likely to outperform the sector on the back of strong fundamentals.

3 Large Biotech Stocks Worth Adding to Your Portfolio

Vir Biotechnology

Their products are seeing a surge in demand.

Now May Be the Big Moment for These 2 COVID Stocks

Sanofi

Sanofi (SNY) and Regeneron (REGN)'s Dupixent meet all primary and secondary endpoints in phase III study to treat children aged six months to five years with moderate-to-severe atopic dermatitis.

Sanofi (SNY)/Regeneron's Dupixent Meets Eczema Study Goal

TARRYTOWN, N.Y. and PARIS, Aug. 30, 2021 /PRNewswire/ -- Dupixent rapidly improved symptoms after first dose, improving itch in one week and skin clearance in two weeks More than seven times as many patients treated with Dupixent plus topical corticosteroids (TCS) achieved clear or almost clear skin compared to TCS alone at week 16 Dupixent plus TCS reduced overall disease severity by 70% and itch by 49% Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive pivotal Phase 3 results from a trial evaluating Dupixent® (dupilumab) to treat moderate-to-severe atopic dermatitis in children aged 6 months to 5 years.

Dupixent® (dupilumab) Pivotal Trial Meets All Primary and Secondary Endpoints Becoming First Biologic Medicine to Significantly Reduce Signs and Symptoms of Moderate-to-severe Atopic Dermatitis in Children as Young as 6 Months

Carrier Global

NVIDIA

We have narrowed down our search to five U.S. corporate bigwigs that have provided more than 10% returns in the past month. These are: MRNA, REGN, AIG, CARR and NVDA.

5 Bigwigs to Buy on Double-Digit Returns in the Past Month

Intuitive Surgical

Microsoft

Look for the current all-time highs to be broken.

3 Growth Stocks Near Record Highs That Are Still Worth Buying

Regeneron's (REGN) phase II study evaluating a higher 8-mg dose of Eylea injection in patients with wet age-related macular degeneration has met the primary safety endpoint.

Regeneron's (REGN) Wet AMD Study on High Dose Eylea Meets Goal

Intuit

Our theme of Cash-Rich Stocks filters for consistently profitable and growing companies within the S&P 500 that have a net cash position (total cash and investments less debt) that stands at 25% or more of their total assets. The theme has outperformed the broader markets considerably, with ytd.

Nvidia, Intuit, Regeneron: Cash-Rich Companies Are Outperforming Big This Year

Apple

Deere & Company

We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.

6 Must-Buy Corporate Giants As Major Indexes Hit Record High

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed new Phase 2 proof-of-concept trial data on Eylea (aflibercept) injection in patients with wet age-related macular degeneration (wet AMD). 43% of wet age-related macular degeneration patients dosed with an 8 mg dose of Eylea reported no retinal fluid after four weeks compared with 26.4% of patients receiving a 2 mg dose of the drug.

Regeneron Touts Mid-Stage Win For Higher Dose Of Eylea In Age-related Macular Degeneration

Kroger

The S&P 500 showed strength to start the new week and hit a new peak on a vaccine boost. This benefited the KR, REGN, TJX, ISRG, MSFT stocks.

5 Stocks At the Forefront of the Latest S&P 500 Rally

TARRYTOWN, N.Y., Aug. 24, 2021 /PRNewswire/ -- Phase 3 trials in wet AMD and diabetic macular edema fully recruited, with results expected in the second half of 2022 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that an ongoing Phase 2 proof-of-concept trial evaluating an investigational 8 mg dose of aflibercept met its primary safety endpoint, with no new safety signals observed compared to the currently-approved 2 mg dose of EYLEA® (aflibercept) Injection in patients with wet age-related macular degeneration (wet AMD).

Regeneron Announces Encouraging Topline Phase 2 Data of High-dose aflibercept in Wet Age-related Macular Degeneration

The shares of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) received a price target of $727 by Benchmark. These are the details.

Regeneron Pharmaceuticals Shares: $727 Target From Benchmark

Regeneron (REGN) gets Conditional Marketing Authorization for its antibody cocktail, casirivimab and imdevimab for COVID-19 infection in the United Kingdom.

Regeneron (REGN) COVID-19 Antibody Cocktail Gets CMA in the UK

Chewy

China Construction Bank Corp

Sturm, Ruger & Company

Vista Outdoor

It is imperative to build a portfolio of low-beta stocks to sail through choppy market conditions. CHWY, REGN, VSTO, RGR & CICHY are the frontrunners.

Combat the Choppy Market With These 5 Low-Beta Stocks

T. Rowe Price Group (TROW), KLA Corporation (KLAC), Whirlpool (WHR), CBRE Group (CBRE) and Regeneron Pharmaceuticals (REGN) are some of the stocks with high ROE to buy as coronavirus resurgence fear soars.

News for Regeneron Pharmaceuticals Stock (REGN)